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Effect of Highly Active Antiretroviral Treatment (HAART)
During Pregnancy on Pregnancy Outcomes:
Experiences from a PMTCT Program in Western India
Shrinivas Darak, BHMS, MA, MSc,1,2 Trupti Darak, BHMS,2 Sanjeevani Kulkarni, LCEH,2 Vinay Kulkarni, MD,2
Ritu Parchure, MBBS, MPH,2 Inge Hutter, PhD,1 and Fanny Janssen, PhD1,3
Abstract
Previous research regarding the effect of highly active antiretroviral treatment (HAART) on pregnancy outcomes
shows conflicting results and is predominantly situated in developed countries. Recently, HAART is rapidly
being scaled up in developing countries for prevention of mother-to-child transmission (PMTCT). This study
compared adverse pregnancy outcomes among HIV infected women (N = 516) who received either HAART
(N = 192)—mostly without protease inhibitor—or antepartum azidothymidine (AZT) with intrapartum nevir-
apine (N = 324) from January 2008 to March 2012 through a PMTCT program in western India. We analyzed the
effect of HAART on preterm births, low birth weight, and all adverse pregnancy outcomes combined using
univariate and multivariate logistic regression models. Women on HAART had 48% adverse pregnancy out-
comes, 25% preterm births, and 34% low birth weight children compared to respectively 32%, 13%, and 22%
among women on AZT. Women receiving HAART were more likely to have adverse pregnancy outcomes and
preterm births compared to women receiving AZT. Preconception HAART was significantly related to low birth
weight children. This study demonstrated increased risk of adverse pregnancy outcomes with protease inhibitor
excluded HAART. Prospective studies assessing the impact of HAART on MTCT as measured in terms of HIV-
free survival among children are needed.
Introduction
While the benefits of highly active antiretroviraltreatment (HAART) for prevention of mother-to-child
transmission of HIV (PMTCT) are undisputed, there have
been some concerns regarding its possible adverse effects on
pregnancy outcomes. Maternal HIV infection has been asso-
ciated with adverse pregnancy outcomes; however, there are
conflicting data regarding effect of HAART during pregnancy
on pregnancy outcomes. While there is an increasing number
of studies that suggest higher risk of preterm birth (PB) (< 37
weeks)1–7 and low birth weight (LBW)2,8–10 among babies of
women receiving HAART during pregnancy, there are also
some studies that did not observe this association.11–16 Most
of the studies are from developed regions4,17–19 and only
recently research findings are emerging from developing
regions.7,20–22 Previous research from developed regions
assessed the role of HAART containing protease inhibitors
(PI), whereas the recent studies from developing regions have
also evaluated the effect of PI excludedHAART on pregnancy
outcomes (Table 1). Overall, studies have reported that
HAART given to HIV-infected pregnant women in the first
trimester (< 13 weeks of pregnancy),21,23–25 Containing
PI20,26–28 and given to women with severe immunosuppres-
sion29 is associated with PB.
Despite the conflicting outcomes on pregnancy outcomes,
HAART is being rapidly scaled up in developing countries for
PMTCT following conclusive studies demonstrating its effi-
cacy in reducing mother-to-child transmission of HIV
(MTCT). Use of HAART can reduce MTCT to < 2% from the
possible 25–30% in the absence of any intervention.30With the
possibility of achieving such low rates of MTCT, the Joint
United Nations, along with partners, have called for ‘‘virtual
elimination’’ ofMTCT; that is, reduction of the number of new
pediatric HIV infections by 90% between 2009 and 2015 and
reduction of MTCT rates to < 5% worldwide.31 As a result of
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the global efforts to provide universal access to PMTCT ser-
vices with more effective protocol, the proportion of women
receiving antiretroviral medicines (ARVs) excluding single
dose nevirapine (sd-NVP) for PMTCT increased from 34% in
2009 to 61% in 2011 worldwide.32
With increasing expansion of HAART in developing
countries and with previous conflicting results of its effect on
pregnancy outcomes, which mainly focused on developed
countries, it is essential to understand the effect of ARVs on
pregnancy outcomes in these developing countries for better
planning and delivery of PMTCT services at the micro and
macro levels.
The objective of this article is to compare the risk of adverse
pregnancy outcomes (APO) among HIV-infected women
(N = 516) who received either HAART (N = 192) or ante-
partum azidothymidine (AZT) with single dose intrapartum
nevirapine (sd-NVP) (N = 324) through a private sector
PMTCT program in Maharashtra, Western India, between
January 2008 to March 2012. We distinguished preterm births
(PB), low birth weight (LBW), and all adverse pregnancy
outcomes (PB, LBW, non-live births) combined (APO) as
outcomes to compare the effect of ARV protocol.
Methods
Setting
The data used in this study were collected prospectively in a
PMTCT program implemented by PRAYAS, a nongovernment
organization located in the city of Pune, inMaharashtra State of
India. Maharashtra has been one of the high HIV prevalence
states in India (HIV prevalence in 2010 was 0.55%).33 The
PRAYAS PMTCT program was initiated in 2002 with the sup-
port fromElizabethGlaser PediatricAIDS Foundation (EGPAF)
and is primarily being implemented in the private health sector.
More than 65% of India’s population access health care in the
private sector for their general health care needs.34 The program
currently reaches approximately 36,000 pregnant women an-
nually through 50 hospitals in 10 districts ofMaharashtra. Since
Table 1. Summary of Selected Recent Literature on HAART and Pregnancy Outcomes
from Developing and Developed Regions
Author; year;
region; (N) ART protocol Findings
Developing regions





Women receiving preconception HAART had higher odds of PB
(AOR: 1.2; CI: 1.1–1.4), SGA (AOR: 1.8; CI: 1.6–2.1) and SB (AOR:
1.5; CI: 1.2–1.8). Initiating HAART in pregnancy (versus AZT)
was associated with higher odds of PB (AOR: 1.4; CI: 1.2–1.8),
SGA (AOR: 1.5; CI: 1.2–1.9), and SB (AOR: 2.5; CI: 1.6–3.9).
Powis et al;20 2011;
Africa; (N = 560)
ABC/AZT/3TC; LPV/
r/AZT/3TC
PI based HAART was most significant factor for preterm birth
(AOR: 2.03; CI: 1.26–3.27)
Marazzi et al;21 2011;
Africa; (N = 3273)
NVP based HAART; no
ART
HAART reduced maternal mortality, PB and abortion/still birth.
However, it had no significant effect on birth weight.
Machado et al;22 2009;
Brazil; (N = 696)




Pre-conception HAART was associated with an increased risk of
PB (AOR: 5.0; CI: 1.5–17.0) and LBW (AOR: 3.6; CI: 1.7–7.7)
Developed regions
Lopez et al;17 2012;
Europe; (N = 519)
NNRTI based HAART;
PI-based HAART;
Increased risk of both spontaneous (AOR: 2.1; CI: 1.5–3.0) and
iatrogenic (AOR: 3.2; CI: 8–5.7) PB among HIV infected women.
However, use of HAART especially in second half of the
pregnancy was associated with iatrogenic PB but not with
spontaneous PB





Compared with monotherapy, HAART was associated with
increased risk of PB in ECS (AOR: 2.4; CI: 1.49–3.86) and NSHPC
(AOR: 1.43; CI: 1.10–1.86) but not in PSD (AOR: 0.92; CI:
0.67–1.26). Heterogeneity in the association was not explained by
study design but may have been the result of substantial
population differences. Pooled analysis showed increased PB
with HAART





HAART with PI was not significantly associated with PB






HAART exposure during pregnancy was associated with an
increased risk of PB (AOR: 3.40; CI: 1.13–10.2) compared with
monotherapy.
ABC, abamune; AOR, adjusted odds ratio; CI, 95% confidence interval; ECS-European Collaborative Study; LBW, low birth weight; LPV/r,
lopinavir boosted with ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor;
NSHPC, National Study of HIV in Pregnancy and Childhood; NVP, nevirapine; PB, preterm birth; PI, protease inhibitor; PSD, Pediatric
Spectrum of HIV Disease project; SB, still birth; SGA, small for gestational age; 3TC, Lamivudine; *Sample size combined for all three databases.
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its inception, the program has provided comprehensive ante-
natal care (ANC) counseling to 255,000 pregnant women at-
tending ANC clinics. After informed consent, 215,000 pregnant
women were tested for HIV, and 1600 HIV infected women
were provided PMTCT services as per the then contemporary
WHO recommended protocols.30,35
After registration in the program, HIV-infected womenwere
followed every month until the assessment of HIV status of the
exposed baby by DNA PCR at the age of 4 months if receiving
replacement feed, or at 3 months after cessation of breastfeed-
ing. Women were informed about breastfeeding, as well as re-
placement feeding, andwere provided support in deciding and
continuing the chosen infant feeding option. Before 2010 WHO
guidelines, exclusive breastfeeding and early cessation of
breastfeeding was recommended to women choosing to
breastfeed. However, after the recent WHO infant feeding
guidelines (2010), the program recommends exclusive breast-
feeding until 6 months and, introducing appropriate comple-
mentary foods thereafter, and continues breastfeeding for the
first 12 months of life. Prophylactic ARV during this period of
breastfeeding is provided to reduce the risk of transmission.
Screening of partners and other children was encouraged
and, if detected to be HIV infected, they were linked to HIV
care. Since 2008, all the HIV-infected women enrolled in the
program underwent baseline CD4 cell counts, with repeat
testing every 6 months. In addition, some women underwent
plasma HIV viral load testing (by RNA PCR), if required for
their treatment.
Data on demographic indicators, obstetric history, HIV
testing, co-morbidities, and treatment were collected at the time
of registration of pregnant women in the PMTCT program and
data on pregnancy outcomes and adherence to treatment pro-
tocol were recorded during follow-up visits. These data were
collected by trained counsellors in structured case report forms
at the hospitals andwere compiled centrally as a part of regular
programmonitoring. Case to case data validationwas regularly
conducted as a part of internal monitoring of the program, and
these data were entered in special software that was developed
for monitoring the PMTCT program.
Study population
HIV-infected women who were registered in the program
from January 2008 to March 2012 (N = 742) were considered
for analysis as CD4 counts were offered to all infected women
from this date. Women who were still pregnant at the time of
data compilation (N = 43), who had opted to terminate their
pregnancy voluntarily (N = 25), who died (N = 3), or were lost
to follow-up before delivery (N = 39), who reported twin
births (N = 7), andwho did not receive any antenatal ARV due
to late presentation in ANC (women who received only sd-
NVP) (N = 109) were excluded from the analysis. Thus, in
total, 516 women with reported pregnancy outcomes were
included in the final analysis (Fig. 1).
We distinguished two groups of women according to ARV
protocol:womenonHAARTversuswomenonAZT.Asper the
then contemporary WHO guidelines, HAART was initiated to
womenwho required treatment for their ownhealth depending
on their CD4 counts (< 350) and disease stage, otherwise AZT
was given along with sd-NVP in labor. Note that women who
presented latewere offered only sd-NVPduring labor as per the
guidelines and they are not included in this study.
Outcome measures
The effect of HAART on pregnancy outcomes was analyzed
using three outcome indicators. Preterm Birth was defined as
when the child was born at <37 weeks of gestation; low birth
weightwas defined as babies having birth weight < 2500g, and
FIG. 1. Pregnancy outcomes among women enrolled in the project.
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a combined indicator of all adverse pregnancy outcomes (APO)
was estimated if the child was born before term (< 37 weeks) or
had lowbirthweight (birthweight < 2500g) or if the pregnancy
did not result in live birth (spontaneous abortions and still-
births). Gestational age was recorded by clinicians based on
ultrasound test (USG) or last menstrual period (LMP) at the
time of delivery. Birth weight was taken soon after delivery
mostly in the labor room. The data on gestational age and birth
weight were collected on a separate delivery note completed by
the clinician after delivery. All women considered for this
analysis delivered at health facilities. Women who reported
non-live births (N= 21) were excluded from the analysis of PB
and LBW children. Data on birth weight were missing for 14
cases mostly because the child was not weighed at birth, either
due to homedeliveryor if the childdied immediately after birth.
Explanatory variables
The data on explanatory variable such as demographic
factors (age, education, occupation, socio-economic status),
obstetric factors (weeks of pregnancy at the time of registra-
tion in the program, parity, past intrauterine death, and level
of anemia) and HIV related factors (CD4 counts, past oppor-
tunistic infections, symptoms of STI during current preg-
nancy) were collected at the time of registration of the women
in the program. Other variables such as duration and adher-
ence of ARV medicines, and Hb% were documented during
follow-up visits.
Statistical analysis
The differences among women who received HAART and
those who received AZT in terms of pregnancy outcomes (PB,
LBW, and non-live births), HIV-related factors, obstetric factors,
and demographic factors were assessed using chi-square tests.
The effect ofARVprotocol onpregnancy outcomeswas analyzed
using independent univariate andmultivariate logistic regression
models for all three outcome variables, the latter by including all
other background HIV-related, obstetric, and demographic var-
iables. Data were analyzed using SPSS (version 20).
Table 2. Comparison of Profile of Women Who Received HAART and Antenatal AZT
Variable Category Total N (%) HAART N (%) AZT N (%) p Value
Pregnancy outcomes
Preterm delivery (N = 495) Yes 85 (17%) 45 (25%) 40 (13%) 0.000
Low birth weight (N = 481) Yes 128 (27%) 60 (34%) 68 (22%) 0.008
Non-live births (N = 516) Yes 21 (4%) 14 (7%) 7 (2%) 0.004
Gestational age at birth (mean) 37.9wk 37.5wk 38.2wk 0.000
Birth weight (mean) 2600.3 g 2555.6 g 2625.5 g 0.236
HIV-related factors
ARV duration = < 12wks 299 (58%) 73 (38%) 226 (70%) 0.000
> 12wks 217 (42%) 119 (62%) 98 (30%)
Abs CD4 < 200 54 (11%) 51 (29%) 3 (1%) 0.000
200–350 118 (25%) 83 (47%) 35 (12%)
350–500 125 (27%) 20 (11%) 105 (36%)
> 500 175 (37%) 24 (14%) 151 (51%)
Past opportunistic infections Yes 85 (17%) 59 (31%) 26 (8%) 0.000
STI symptoms in pregnancy Yes 69 (13%) 27 (14%) 42 (13%) 0.723
Obstetric factors
Pregnancy weeks (mean) 24wks 22wks 25wks 0.000
Parity 1st pregnancy 178 (35%) 47 (25%) 131 (40%) 0.001
2nd pregnancy 186 (36%) 76 (40%) 110 (34%)
3rd and above 152 (30%) 69 (36%) 83 (26%)
Past intrauterine death/abortion Yes 152 (30%) 60 (31%) 92 (28%) 0.492
Anemia (Hb g/dl) Severe ( < 7) 15 (3%) 9 (6%) 6 (2%) 0.120
Moderate (7–9.9) 174 (36%) 55 (34%) 119 (38%)
Mild (10–10.9) 133 (28%) 49 (30%) 84 (27%)
No anemia (> = 11) 158 (33%) 50 (31%) 108 (34%)
Demographic factors
Age 16–20 66 (13%) 8 (4%) 58 (18%) 0.000
21–25 234 (45%) 84 (44%) 150 (46%)
26–30 152 (30%) 68 (35%) 84 (26%)
> = 31 64 (12%) 32 (17%) 32 (10%)
Education No schooling 82 (16%) 34 (18%) 48 (15%) 0.619
School 1st to 10th 289 (56%) 103 (54%) 186 (58%)
College and above 143 (28%) 54 (28%) 89 (28%)
Occupation Working 109 (21%) 49 (26%) 60 (19%) 0.060
Not working 407 (79%) 143 (75 %) 264 (82%)
Socioeconomic status Poor 182 (36%) 65 (35%) 117 (36%) 0.344
Middle class 308 (61%) 113 (60%) 195 (61%)
Rich 19 (4%) 10 (5%) 9 (3%)
Total N 516 192 324











































































































































































































































































































































































































































































































































































































Of the 516 women who reported pregnancy outcome, 37%
(192) received HAART and 63% (324) received antenatal AZT
(Fig. 1). Comparison of the profile of women according to the
protocol they received is given in Table 2. In general, any
adverse pregnancy outcome (APO) was observed among 45%
women, 17% children were born preterm, and 27% children
had LBW. Significantly higher proportion of women who re-
ceived HAART had children born preterm, had LBW children
and non-live births (Table 2). Average gestational age of babies
born to women who received HAART was 37.47 weeks (95%
CI, 37.11–37.82) and 38.22 weeks (95% CI, 38.06–38.39) among
women who received AZT. Eleven per cent of the women had
advanced immunological suppression (CD4< 200) at the time
of pregnancy and almost all were from the HAART group.
Among the HAART group, 71% had CD4> 200 at the time of
pregnancy which is due to receiving HAART prior to concep-
tion and related improvement from this treatment. Among the
17% of women who had opportunistic infections in the past
such as tuberculosis, herpes zoster, and oral candidiasis, a
significantly higher proportion of women were in the HAART
group (31% vs. 8%, p= 0.000). A higher proportion of women
who received HAART had registered early in their pregnancy
and had 3rd or higher order parity (36% vs. 26%, p= 0.001)
compared to women who received AZT. Severe to moderate
anaemia (< 10g/dL) was observed among 39% of the women
and therewas no statistically significant difference according to
the protocol they received. The mean age of women was 25
years (SD– 4.5 years). The mean age of women who received
HAART was significantly higher (27 years, SD– 4) than wo-
men who received AZT (25 years, SD– 4) ( p= 0.000). Sixteen
per cent of women had no education, 21% had remunerated
activity, and 36%were from poor socioeconomic backgrounds;
there was no statistically significant difference among women
in both the groups.
Crude and adjusted risk ratios (RR) of ARV protocol and
significant variables for PB, LBW, and APO are shown in
Table 3. In the univariate model, women who received
HAART and had CD4 count< 200 were significantly more
likely to experience PB, have LBW children, and experience
APO compared to women who received AZT and who had
CD4 count> 500, respectively (Table 3). In the multivariate
model after controlling for the effect of HIV related, obstetric,
and demographic factors, womenwho receivedHAARTwere
3.4 times more likely [RR 3.350, 95% CI 1.520–7.383] to ex-
perience PB and 1.9 timesmore likely [RR 1.949, 95%CI 1.099–
3.454] to experience APO in comparison to women who
received AZT. Younger women (age 16–20) were also 3.4 times
more likely [RR 3.370, 95% CI 1.031–11.012] to experience
preterm birth in comparison to the older women (age > = 31).
Discussion
Women who received HAART—mostly without PI—were
3.4 timesmore likely to experience preterm birth and 1.9 times
more likely to experience all adverse pregnancy outcomes in
comparison to the women who received AZT with sd-NVP,
after controlling for the effect of other HIV-related, obstetric,
and demographic factors.
Effects of HAART on increased preterm birth have been
documented from developed countries in Europe and
USA5,6,17,21 and recently from Africa.11,23,36 This is the first
study from India to demonstrate increased risk of preterm
birth among children born to women receiving HAART
during pregnancy. Average weeks at the time of delivery
among women who received HAART was 37.74 (95% CI,
37.11–37.82) and 38.22 (95% CI, 38.06–38.39) among women
who received AZT and very preterm births (between 28–32
weeks of pregnancy) was observed among 13 children, all but
one were born to women who had received HAART. The
rates of preterm birth observed in this study (25% in HAART
and 13% in AZT group) were similar to the rates observed in
Mma Bana study in Botswana.23 However, women in the
Botswana study were randomized to receive the PI-based
protocol. One of the studies from Maharashtra India37 com-
pared pregnancy outcomes among HIV-infected women (not
on HAART) with HIV-uninfected women and reported no
statistically significant differences in pregnancy outcomes in
both the groups. This substantiates the findings of our study
that HAART could be a potential risk factor for preterm birth.
Our study—alongwith a few others9,25—has demonstrated
the increased risk of adverse pregnancy outcomes, particu-
larly PB, among children of womenwho received other than a
PI-based combination. The majority of the women receiving
HAART in our study were taking 2 nucleoside reverse tran-
scriptase inhibitors (NRTIs) and 1 non-nucleoside reverse
transcriptase inhibitor (NNRTI) combination (97%) and only 6
women received PI-based combination. The initial studies
investigating the effect of HAART on preterm birth have in-
dicated increased risk of PB, mostly with PI-based combina-
tion ARTwhere the effect of PI was compared with NRTI and
NNRTI combination.22,23
The risk of having babies with LBW was higher among
women who received HAART compared to women who re-
ceived AZT. However, this relationship was not statistically
significant in the multivariate analysis. Nine per cent of the all
babies (N = 41) had very low birth weight ( < 2000 g) with
significantly higher proportion among women who had re-
ceived HAART (13%) compared to women who had received
AZT (6%) ( p= 0.006). In an additional multivariate analysis
that distinguished women taking HAART prior to conception
(N = 61) and HAART initiated during antenatal period
(N = 131), preconception HAART was significantly associated
with increased risk of LBW [AOR 2.843, 95% CI 1.261–6.409]
compared to antenatal AZT.
The association of preconception HAART and LBW among
babies has been reported earlier for Botswana,11,30,38 Brazil,22
and Cote d’Ivoire.9 In the study by Parekh et al.10 from
Botswana which compared antenatal AZT with HAART,
preconception HAART was associated with very-small-
for-gestational births but not with PB, whereas another study
from the same country that assessed the effect of in utero ex-
posure of HAART on longitudinal growth of uninfected
children found significant LBW among infants exposed to
HAART as compared to AZT-exposed infants.31 The study
also concluded that lower weights in HAART exposed unin-
fected infants were rapidly corrected during the first 6months
of life.31 While the exact pathophysiological mechanism of
preconception HAART and LBW is not known, there is a need
for further prospective studies that would also account for
important predictors of birth weight such as maternal nutri-
tion status. The data on maternal nutritional status, which is
one of the known predictors of birth weight,39 were lacking in
our study.
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Women who received HAART were more likely to ex-
perience any adverse pregnancy outcome. A combined in-
dicator of adverse pregnancy outcome, which also included
spontaneous abortions and stillbirths in addition to PB and
LBW, was estimated in order to assess the overall magni-
tude of adverse pregnancy outcome with respect to the
protocol. A previous study based on data from the third
round of the National Family Health Survey in India has
shown that the risk of spontaneous abortions and still births
is higher among HIV infected women who were unaware
about their HIV status, compared to HIV-negative wom-
en.40 However, limited research is available on the effect of
HAART on fetal death41 and a recent pooled analysis of
studies showed that HAART did not reduce the possibility
of stillbirths.42
In our study, in spite of the better CD4 counts at the time of
pregnancy due to treatment (HAART), the group of women
who received HAART might be clinically different than the
women who received AZT. However, a recent study by Bar-
oncelli and colleagues43 among women who were diagnosed
before pregnancy and undergoing ART at conception re-
ported that women who have not experienced AIDS-defining
events have similar maternal and neonatal outcomes as
compared to women with more advanced stage of the dis-
ease.43 Thus it is less likely that a past history of AIDS defining
illness would affect pregnancy outcomes.
This study has demonstrated a high risk of adverse preg-
nancy outcomes, particularly preterm birth, among HIV-
infected Indian women receiving HAART not containing PI
through a private sector PMTCT program in Maharashtra.
The reliability of the data was checked consistently during the
program implementation. However, the possibility of certain
measurement errors, particularly in recording birth weight,
cannot be ruled out as the measurements were taken by dif-
ferent people and the measuring device was not standard
across sites. Despite these limitations, the results clearly in-
dicate the need for further in-depth prospective study to de-
termine the magnitude of adverse pregnancy outcomes
among HIV-infected women receiving HAART and the
health care needs of these children.
The Indian national program for prevention of mother to
child transmission is likely to rollout HAART (option B).
While the benefits of HAART must be provided to pregnant
women, there is a need to address certain knowledge gaps
associated with rolling out HAART for PMTCT. Well-
designed prospective studies are needed to understand the
impact of HAART onMTCT asmeasured in terms of HIV-free
survival among children. Adherence to HAART during
pregnancy and in postpartum period, which was shown to be
significantly lower in one of the recent studies in Latin
America,44 should be assessed among Indian women.
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